Latest radiation therapy Stories

Chemo Patients Benefit From Hair Circadian Clock

Hair's Circadian Clock May Help Reduce Hair Loss In Chemo Patients

2013-05-21 10:00:16

redOrbit Staff & Wire Reports - Your Universe Online The discovery that mouse hair operates on a circadian clock has given researchers hope that cancer radiotherapy and chemotherapy could be scheduled later in the day in order to minimize hair loss in patients. According to the study, which was published online Monday in the Proceedings of the National Academy of Sciences (PNAS), experts from the Salk Institute for Biological Studies, the University of Southern California (USC) and...

New Data Validates CyberKnife SBRT for Prostate Cancer Treatment

2013-05-21 08:29:54

Updated ASTRO Model Policy Endorses Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer SUNNYVALE, Calif., May 21, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System, the most widely used form of prostate stereotactic body radiation therapy (SBRT). The study followed 304 patients for a median of 5 years, and many...

Landauer, Inc. Declares Regular Cash Dividend

2013-05-20 16:22:29

GLENWOOD, Ill., May 20, 2013 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, announced today that its Board of Directors declared, at its meeting on May 16, 2013, a regular quarterly cash dividend of $0.55 per share for the third quarter of fiscal 2013. The dividend will be paid on July 3, 2013, to shareholders of...

Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients

2013-05-17 08:24:08

Linear accelerator is island's first Versa HD PONCE, Puerto Rico, May 17, 2013 /PRNewswire/ -- Serving a region of 650,000 inhabitants in southern, central and western Puerto Rico, Caribbean Imaging and Radiation Therapy (CIRT, Ponce, PR) Center has improved its radiation therapy capabilities with the acquisition of an Elekta Versa HD(TM) system, the first in Puerto Rico. Versa HD offers clinicians the versatility to deliver conventional therapies to treat a wide range of tumors...

Novelos Therapeutics Provides Product Pipeline Update

2013-05-16 08:28:29

To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 MADISON, Wis., May 16, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today provided an update on its product pipeline, including I-124-CLR1404 (LIGHT) positron emission tomography (PET) imaging agent for solid tumor indications, I-131-CLR1404 (HOT) cancer-targeted molecular...

Skin Cancer Awareness Month: An Unlikely Patient

2013-05-15 23:02:40

Los Angeles Cancer Institute team member shares her personal journey of overcoming skin cancer. Los Angeles, CA (PRWEB) May 15, 2013 When 60-year-old Edna Mayorga first accepted a job with the large cancer care provider, Los Angeles Cancer Institute, a division of 21st Century Oncology of California, she did not know she would eventually become a patient. In November 2012, the 16-year veteran Patient Care Coordinator was diagnosed with basal cell carcinoma – skin cancer on her nose....

Bayer Receives U.S. FDA Approval for Xofigo® (radium Ra 223 dichloride) Injection as a New Treatment for Castration-Resistant Prostate Cancer with Bone Metastases

2013-05-15 12:34:17

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo(®) (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first and only alpha particle-emitting radioactive therapeutic agent approved by the FDA that has demonstrated...

New Drug Enhances Radiation Treatment For Brain Cancer In Preclinical Studies

2013-05-15 10:32:53

A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy. Recently published in the journal Clinical Cancer Research, the study provides the first preclinical evidence demonstrating that an ATM kinase...

Radiotherapy Market is Expected to Grow at a Faster Rate with a CAGR of 5.3% & to Reach $5.8 Billion by 2016 - New Report by MarketsandMarkets

2013-05-10 23:23:07

[311 Pages Report] The Radiotherapy Devices Market Report segments global market of Monitoring Devices by various technologies Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Cyber knife, Gamma knife, Proton / Neutron Therapy, Dynamic Multi-Leaf Collimator (DMLC) and by Geography (PRWEB) May 10, 2013 The “Radiotherapy Market By Technology, Applications & Products (2011 – 2016)”, published by MarketsandMarkets analyzes and studies the major...

Canada's Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy

2013-05-10 08:25:18

Research projects to have implications for cancer treatment worldwide TORONTO, May 10, 2013 /PRNewswire/ -- Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy. Sunnybrook Health Sciences Centre, the sixth largest cancer center in North America, is the fourth member to sign the research...